Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vericel Corporation (VCEL)

Vericel Corporation (VCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -23.08% and 6.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

VCEL : 52.02 (-0.59%)
PRQR : 2.29 (-3.78%)
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 1.19% and 19.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

RPTX : 4.71 (+0.86%)
VCEL : 52.02 (-0.59%)
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of 2.75% and 6.31%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

TWST : 34.31 (-0.49%)
VCEL : 52.02 (-0.59%)
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 28.93% and 3.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ALNY : 149.45 (-3.20%)
VCEL : 52.02 (-0.59%)
Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

/PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments...

SGTX : 22.47 (-2.56%)
ATRS : 5.59 (unch)
VCEL : 52.02 (-0.59%)
Allogene Therapeutics (ALLO) Surges 8.4%: Is This an Indication of Further Gains?

Allogene Therapeutics (ALLO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...

ALLO : 4.47 (+0.22%)
VCEL : 52.02 (-0.59%)
Vericel Corporation (VCEL) Q4 Earnings Surpass Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 500% and 0.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

VCEL : 52.02 (-0.59%)
LQDA : 14.75 (-2.12%)
Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?

Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

VCEL : 52.02 (-0.59%)
ABUS : 2.58 (-0.77%)
Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors

Kytopen , an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to...

VCEL : 52.02 (-0.59%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

VCEL : 52.02 (-0.59%)
OCEL : 2.7500 (unch)
BRTX : 1.3800 (-0.91%)
MDXG : 7.70 (+1.18%)
NNVC : 1.1600 (+2.65%)

Barchart Exclusives

Ford Motor vs. Toyota: Which Hybrid EV Stock Is a Better Buy?
With hybrid EVs gaining popularity, let’s find out whether shares of Ford or Toyota are a better buy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar